Primary lateral sclerosis (PLS) is a rare neurodegenerative disease in which the nerve cells that control voluntary movement, called upper motor neurons, slowly break down. Unlike ALS, which affects both upper and lower motor neurons and is typically fatal within a few years, PLS progresses much more slowly. Median survival from symptom onset is about 23 years, and the median age at death is around 79.5 years, only slightly below the general population average.
How PLS Affects the Nervous System
Your brain controls movement through a circuit that starts in the motor cortex, a strip of tissue near the top of the brain. Large nerve cells there, called upper motor neurons, send long projections (axons) down through the spinal cord to relay movement signals to the rest of the body. In PLS, these neurons progressively degenerate.
The damage begins at a cellular level. The branching structures on these neurons that receive signals from neighboring cells start to shrink and lose their connections. The internal transport system that moves proteins and energy along the neuron’s long axon begins to fail. Mitochondria, the structures that produce energy inside each cell, develop defects, starving the neuron of fuel. At the same time, the immune response in the brain ramps up, with inflammatory cells becoming more active around the affected areas. This combination of energy failure, structural breakdown, and inflammation drives the slow, progressive loss of motor control that defines the disease.
Early Symptoms and How They Progress
PLS typically begins after age 25, and most people are diagnosed in their 40s or 50s. The earliest and most distinctive symptom is stiffness. In a study comparing PLS and ALS patients, 47% of people with PLS reported stiffness as their initial complaint, compared to just 4% of those with ALS. This stiffness, called spasticity, usually starts in the legs and gradually worsens, making walking feel slow and effortful.
Over months to years, stiffness and weakness can spread to the arms and hands, making fine motor tasks like buttoning a shirt or writing more difficult. In some people, the muscles controlling speech and swallowing eventually become involved. This is called bulbar involvement, and it can cause slurred or slow speech, difficulty swallowing, and sometimes episodes of involuntary laughing or crying that don’t match what the person is actually feeling. Not everyone develops bulbar symptoms, and when they do appear, it’s often years into the disease.
A key feature that separates PLS from ALS is the absence of muscle wasting. During follow-up in one study, limb wasting appeared in only 2% of PLS patients compared to 100% of ALS patients. This is because PLS spares the lower motor neurons, the cells that connect directly to muscles. When those cells die (as they do in ALS), muscles shrink visibly. In PLS, muscles stay intact but become stiff and hard to control.
How PLS Differs From ALS
The distinction between PLS and ALS matters enormously because the two diseases have very different outlooks. ALS attacks both upper and lower motor neurons, progresses rapidly, and has a median survival of about three to five years. PLS affects only the upper motor neurons, progresses slowly, and allows a near-normal lifespan for many people.
The challenge is that in the early stages, the two can look similar. Some people initially diagnosed with PLS later develop lower motor neuron signs and are reclassified as having ALS. For this reason, doctors require a long observation period before confirming PLS. A diagnosis is considered “probable” if no lower motor neuron involvement appears within two to four years of symptom onset, and “definite” only after four or more years. Nerve conduction studies and electromyography (EMG) are used to check whether lower motor neurons are being affected.
The current consensus diagnostic criteria require that the person be at least 25 years old, have progressive upper motor neuron symptoms for at least two years, and show signs of dysfunction in at least two of three body regions: legs, arms, or the muscles controlling speech and swallowing. Sensory symptoms like numbness or tingling point away from PLS, since the disease targets motor pathways exclusively.
Genetics and Who Gets PLS
The vast majority of adult-onset PLS cases are sporadic, meaning they occur without a known genetic cause or family history. There is a separate, much rarer juvenile form that begins in childhood and is linked to mutations in the ALS2 gene. This juvenile form is inherited in an autosomal recessive pattern, meaning a child must receive a copy of the mutated gene from each parent. However, research has confirmed that adult-onset PLS is not associated with mutations in the ALS2 gene, and the two conditions do not overlap clinically.
PLS is rare by any measure. Exact incidence figures are hard to pin down because of its rarity and the long observation period needed for diagnosis, but it accounts for a small fraction of motor neuron disease cases overall.
Treatment and Symptom Management
No treatment currently exists to prevent, stop, or reverse PLS. Management focuses entirely on relieving symptoms and helping people maintain function for as long as possible.
Spasticity is the primary target. Oral medications that relax muscles, such as baclofen, tizanidine, and dantrolene, are commonly prescribed. Nerve-calming medications like gabapentin and pregabalin can also help. If these aren’t enough, a small pump can be surgically implanted to deliver medication directly to the spinal fluid, which often provides better relief with fewer side effects than oral doses.
Physical therapy plays a central role. Regular stretching and strengthening exercises help preserve flexibility, prevent joints from becoming locked in place, and maintain whatever range of motion exists. As the disease progresses, therapists periodically assess whether assistive devices like braces, canes, walkers, or wheelchairs would help with mobility and safety.
For people who develop speech difficulties, working with a speech-language pathologist can help maximize communication ability. If involuntary emotional episodes become disruptive, antidepressant medications can reduce their frequency and intensity. Drooling, which sometimes occurs when swallowing muscles are affected, can be managed with medications that reduce saliva production or with targeted injections to the salivary glands.
Living With PLS Long-Term
Because PLS progresses slowly, many people live with the condition for decades. The median survival of about 23 years from symptom onset means that someone diagnosed at 50 can reasonably expect to live into their 70s or beyond. The disease does progressively limit mobility and, in some cases, communication, but it does not typically affect thinking, memory, or sensation.
The slow pace of progression allows time to adapt. Many people transition gradually from walking unaided, to using a cane, to relying on a wheelchair over the course of many years. Planning ahead for these transitions, including home modifications and workplace accommodations, can make a meaningful difference in quality of life. Because PLS is so rare, connecting with specialized motor neuron disease clinics, where teams are familiar with the condition, tends to result in better coordinated care than seeing individual specialists in isolation.